drugset / Trial / NCT05628857

A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor

NCT05628857

Phase 2 Completed 29 enrolled RemeGen Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A multi-center, open-label, study designed to evaluate the preliminary efficacy, safety and pharmacokinetics of RC108 in patients with c-Me-positive advanced digestive system malignancies.

Timeline

Start
2022-11-11
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject RC108 Other / unclassified Intravenous